ALEJANDRO
FONOLLOSA CALDUCH
Hospital Universitario Doctor Peset
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Doctor Peset (9)
2024
-
Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©
Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682
2023
-
Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)
Ophthalmology and Therapy
-
Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis
Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055
2022
-
Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study
BMJ open, Vol. 12, Núm. 3, pp. e051378
-
Vogt-Koyanagi-Harada disease in Spain
European Journal of Ophthalmology, Vol. 32, Núm. 3, pp. 1547-1554
2020
-
Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy
Ocular Immunology and Inflammation, pp. 1-8
-
Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group
Ophthalmology
2017
-
Development of an activity disease score in patients with uveitis (UVEDAI)
Rheumatology International, Vol. 37, Núm. 4, pp. 647-656
2014
-
AB0571 High Dose Intravenous Methylprednisolone Induces RAPID Improvement in Severe Ocular Inflammation. Multicenter Study of 104 Cases
Annals of the Rheumatic Diseases, Vol. 73, Núm. Suppl 2, pp. 995.1-995